LifeMD Statistics
Total Valuation
LifeMD has a market cap or net worth of $187.10 million. The enterprise value is $156.64 million.
Important Dates
The last earnings date was Monday, March 9, 2026, after market close.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LifeMD has 47.97 million shares outstanding. The number of shares has increased by 9.55% in one year.
| Current Share Class | 47.97M |
| Shares Outstanding | 47.97M |
| Shares Change (YoY) | +9.55% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 14.22% |
| Owned by Institutions (%) | 39.72% |
| Float | 39.45M |
Valuation Ratios
The trailing PE ratio is 16.63 and the forward PE ratio is 47.97.
| PE Ratio | 16.63 |
| Forward PE | 47.97 |
| PS Ratio | 0.96 |
| Forward PS | 0.82 |
| PB Ratio | 7.86 |
| P/TBV Ratio | 15.22 |
| P/FCF Ratio | 29.19 |
| P/OCF Ratio | 22.60 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 13.93 |
| EV / Sales | 0.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 24.44 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.25 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.99 |
| Interest Coverage | -5.64 |
Financial Efficiency
Return on equity (ROE) is -131.16% and return on invested capital (ROIC) is -20.46%.
| Return on Equity (ROE) | -131.16% |
| Return on Assets (ROA) | -6.54% |
| Return on Invested Capital (ROIC) | -20.46% |
| Return on Capital Employed (ROCE) | -26.60% |
| Weighted Average Cost of Capital (WACC) | 15.38% |
| Revenue Per Employee | $551,293 |
| Profits Per Employee | $31,954 |
| Employee Count | 352 |
| Asset Turnover | 2.65 |
| Inventory Turnover | 9.95 |
Taxes
In the past 12 months, LifeMD has paid $45,721 in taxes.
| Income Tax | 45,721 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.82% in the last 52 weeks. The beta is 2.01, so LifeMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -31.82% |
| 50-Day Moving Average | 3.38 |
| 200-Day Moving Average | 6.31 |
| Relative Strength Index (RSI) | 58.36 |
| Average Volume (20 Days) | 1,520,682 |
Short Selling Information
The latest short interest is 6.46 million, so 13.47% of the outstanding shares have been sold short.
| Short Interest | 6.46M |
| Short Previous Month | 5.72M |
| Short % of Shares Out | 13.47% |
| Short % of Float | 16.38% |
| Short Ratio (days to cover) | 7.50 |
Income Statement
In the last 12 months, LifeMD had revenue of $194.06 million and earned $11.25 million in profits. Earnings per share was $0.25.
| Revenue | 194.06M |
| Gross Profit | 166.34M |
| Operating Income | -7.67M |
| Pretax Income | -10.19M |
| Net Income | 11.25M |
| EBITDA | -6.71M |
| EBIT | -7.67M |
| Earnings Per Share (EPS) | $0.25 |
Full Income StatementBalance Sheet
The company has $36.79 million in cash and $6.32 million in debt, with a net cash position of $30.46 million or $0.63 per share.
| Cash & Cash Equivalents | 36.79M |
| Total Debt | 6.32M |
| Net Cash | 30.46M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 23.16M |
| Book Value Per Share | 0.50 |
| Working Capital | 10.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.28 million and capital expenditures -$1.87 million, giving a free cash flow of $6.41 million.
| Operating Cash Flow | 8.28M |
| Capital Expenditures | -1.87M |
| Depreciation & Amortization | 959,526 |
| Net Borrowing | -18.72M |
| Free Cash Flow | 6.41M |
| FCF Per Share | $0.13 |
Full Cash Flow StatementMargins
Gross margin is 85.72%, with operating and profit margins of -3.95% and 7.40%.
| Gross Margin | 85.72% |
| Operating Margin | -3.95% |
| Pretax Margin | -5.25% |
| Profit Margin | 7.40% |
| EBITDA Margin | -3.46% |
| EBIT Margin | -3.95% |
| FCF Margin | 3.30% |
Dividends & Yields
LifeMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.55% |
| Shareholder Yield | -9.55% |
| Earnings Yield | 6.01% |
| FCF Yield | 3.43% |
Analyst Forecast
The average price target for LifeMD is $9.14, which is 134.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.14 |
| Price Target Difference | 134.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on October 14, 2020. It was a reverse split with a ratio of 1:5.
| Last Split Date | Oct 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
LifeMD has an Altman Z-Score of 2.12 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.12 |
| Piotroski F-Score | 4 |
